Pharmacokinetics, safety and tolerability of EDP 239 in healthy volunteers

Trial Profile

Pharmacokinetics, safety and tolerability of EDP 239 in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2015

At a glance

  • Drugs EDP 239 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Enanta Pharmaceuticals
  • Most Recent Events

    • 23 Oct 2015 New trial record
    • 18 Sep 2015 Results presented at Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top